Synthesis and biological activity of novel barbituric and thiobarbituric acid derivatives against non-alcoholic fatty liver disease

European Journal of Medicinal Chemistry

Volumn 46, Issue 6, 2011, Pages 2003-2010

  Ma, Liang ^a   Li, Shilin ^a   Zheng, Hao ^a   Chen, Jinying ^a   Lin, Lin ^b   Ye, Xia ^a   Chen, Zhizhi ^a   Xu, Qinyuan ^a   Chen, Tao ^a   Yang, Jincheng ^a   Qiu, Neng ^a   Wang, Guangcheng ^a   Peng, Aihua ^a   Ding, Yi ^b   Wei, Yuquan ^a   Chen, Lijuan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Adiponectin expression; Barbituric acid; Insulin resistance; NAFLD

Indexed keywords

2 (4 ((4,6 DIOXO 2 THIOXOTETRAHYDROPYRIMIDIN 5(6H) YLIDENE)METHYL)PHENOXY) N (5 METHYLPYRIDIN 2 YL)ACETAMIDE; ADIPONECTIN; BARBITURIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; N (3,4 DIFLUOROPHENYL) 2 (4 ((2,4,6 TRIOXOTETRAHYDROPYRIMIDIN 5(6H) YLIDENE)METHYL)PHENOXY)ACETAMIDE; N (PYRIDIN 2 YL) 2 (4 ((2,4,6 TRIOXOTETRAHYDROPYRIMIDIN 5(6H) YLIDENE)METHYL)PHENOXY)ACETAMIDE; N PHENYL (4 ((2,4,6 TRIOXOTETRAHYDROPYRIMIDIN 5(6H) YLIDENE)METHYL)PHENOXY)ACETAMIDE; ROSIGLITAZONE; THIOBARBITURIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IN VITRO STUDY; INTRAABDOMINAL FAT; LIPID DIET; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; LIVER WEIGHT; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; RAT;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ADIPONECTIN; ANIMALS; BARBITURATES; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; FATTY LIVER; LEPTIN; MALE; MICE; MOLECULAR STRUCTURE; RATS; RATS, WISTAR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIOBARBITURATES;

EID: 79955578824     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.02.033     Document Type: Article

References (27)

1. A. Paul, Non-alcoholic fatty liver disease, N. Engl. J. Med. 346 (2002) 1221-1231.
2. L.A. Adams, A. Paul, Treatment of non-alcoholic fatty liver disease, Postgrad. Med. J. 82 (2006) 315-322.
3. G.C. Farrell, Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J. Gastroenterol. Hepatol. 18 (2003) 124-138.
4. C.P. Day, Non-alcoholic fatty liver disease: current concepts and management strategies, Clin. Med. 6 (2006) 19-25.
5. C.A. Matteoni, Z.M. Younossi, T. Gramlich, N. Boparai, Y.C. Liu, A.J. McCullough, Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity, Gastroenterology 116 (1999) 1413-1419. (Pubitemid 29258890)
6. G. Marchesini, R. Marzocchi, F. Agostini, Non-alcoholic fatty liver disease and the metabolic syndrome, Curr. Opin. Lipidol. 16 (2005) 421-427. (Pubitemid 41017626)
7. S. Chitturi, S. Abeygunasekera, G.C. Farrell, J. Holmes-Walker, J.M. Hui, C. Fung, NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome, Hepatology 35 (2002) 373-379. (Pubitemid 34106377)
8. G. Marchesini, M. Brizi, G. Bianchi, S. Tomassetti, E. Bugianesi, M. Lenzi, Non-alcoholic fatty liver disease: a feature of the metabolic syndrome, Diabetes 50 (2001) 1844-1850. (Pubitemid 33641605)
9. G. Marchesini, E. Bugianesi, G. Forlani, F. Cerrelli, M. Lenzi, R. Manini, Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome, Hepatology 37 (2003) 917-923.
10. A.H. Berg, T.P. Combs, P.E. Scherer, ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism, Trends Endocrinol. Metab. 13 (2002) 84-89.
11. C.S. Mantzoros, The role of leptin in human obesity and disease: a review of current evidence, Ann. Intern. Med. 130 (1999) 671-680. (Pubitemid 29196202)
12. J. Nedvidkova, K. Smitka, V. Kopsky, V. Hainer, Adiponectin, an adipocyte-derived protein, Physiol. Res. 54 (2005) 133-140.
13. J.P. Whitehead, A.A. Richards, I.J. Hickman, G.A. Macdonald, J.B. Prins, Adiponectin-a key adipokine in the metabolic syndrome, Diabetes Obes. Metab. 8 (2006) 264-280.
14. A. Xu, Y. Wang, H. Keshaw, L.Y. Xu, K.S.L. Lam, G.J.S. Cooper, The fat-derived hormone adiponectin alleviates alcoholic and non-alcoholic fatty liver diseases in mice, J. Clin. Invest. 112 (2003) 91-100.
15. K. Hotta, T. Funahashi, Y. Arita, M. Takahashi, M. Matsuda, Y. Okamoto, H. Iwahashi, H. Kuriyama, N. Ouchi, K. Maeda, M. Nishida, S. Kihara, N. Sakai, T. Nakajima, K. Hasegawa, M. Muraguchi, Y. Ohmoto, T. Nakamura, S. Yamashita, T. Hanafusa, Y. Matsuzawa, Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients, Arterioscler. Thromb. Vasc. Biol. (2000) 1595-1599.
16. N. Valerio, M. Melania, C. Paolo, D. Vincenzo, D. Rita, P. Fiorella, C. Roberto, G. Donatella, M. Matilde, Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease, Eur. J. Endocrinol. 155 (2006) 735-743.
17. H.Z. Lin, S.Q. Yang, C. Chuckaree, Metformin reverses fatty liver disease in obese, leptin-deficient mice, Nat. Med. 6 (2000) 998-1003.
18. E. Bugianesi, E. Gentilcore, R. Manini, S. Natale, E. Vanni, N. Villanova, A randomized controlled trial of metformin versus vitamin E or prescriptive diet in non-alcoholic fatty liver disease, Am. J. Gastroenterol. 100 (2005) 1082-1090.
19. D. Kirpichnikov, S.I. McFarlane, J.R. Sowers, Metformin: an update, Ann. Intern. Med. 137 (2002) 25-33. (Pubitemid 34705373)
20. H. Hans, The mode of action of thiazolidinediones, Diabetes Metab. Res. Rev. 18 (2002) 10-15.
21. N. Maeda, I. Shimomura, K. Kishida, H. Nishizawa, M. Matsuda, H. Nagaretani, N. Furuyama, H. Kondo, M. Takahashi, Y. Arita, R. Komuro, N. Ouchi, S. Kihara, Y. Tochino, K. Okutomi, M. Horie, S. Takeda, T. Aoyama, T. Funahashi, Y. Matsuzawa, Diet-induced insulin resistance in mice lacking adiponectin/ACRP30, Nat. Med. 8 (2002) 731-737.
22. W.S. Yang, C.Y. Jeng, T.J. Wu, S. Tanaka, T. Funahashi, Y. Matsuzawa, J.P. Wang, C.L. Chen, T.Y. Tai, L.M. Chuang, Synthetic peroxisome proliferator -activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients, Diabetes Care 25 (2002) 376-380.
23. N. Riera-Guardia, D. Rothenbacher, The effect of thiazolidinediones on adiponectin serum level: a meta-analysis, Diabetes Obes. Metab. 10 (2008) 367-375.
24. V. Ratziu, P. Giral, S. Jacqueminet, F. Charlotte, A. Hartemann-Heurtier, L. Serfaty, P. Podevin, J.M. Lacorte, C. Bernhardt, E. Bruckert, A. Grimaldi, T. Poynard, Rosiglitazone for non-alcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone therapy (FLIRT) Trial, Gastroenterology 135 (2008) 100-110. (Pubitemid 351916703)
25. B.A. Neuschwander-Tetri, E.M. Brunt, K.R. Wehmeier, D. Oliver, B.R. Bacon, Improved non-alcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone, Hepatology 38 (2003) 1008-1017. (Pubitemid 37221684)
26. S. Sandeep, V. Bhoomi, R. Poduri, K.C. Asit, V.B. Prasad, New PPAR g ligands based on barbituric acid: virtual screening, synthesis and receptor binding studies, Bioorg. Med. Chem. Lett. 18 (2008) 4959-4962.
27. P. Vincent, K. Jasna, C. David, D.C. Dennis, P.S. Jeffrey, R. Karen, B.C. Fabienne, V. Delphine, C. Montserrat, C. Christian, G. Corinne, F. Bernard, P. Dominique, L. Didier, G. Denise, N. Anthony, A.V. Pierre, C. Susanna, R. Christian, K.S. Matthias, R. Thomas, Furan-2-ylmethylene Thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase g, J. Med. Chem. 49 (2006) 3857-3871.